U.S. markets open in 9 hours 21 minutes
  • S&P Futures

    4,071.75
    +13.00 (+0.32%)
     
  • Dow Futures

    33,608.00
    +100.00 (+0.30%)
     
  • Nasdaq Futures

    13,051.50
    +53.00 (+0.41%)
     
  • Russell 2000 Futures

    2,141.60
    +10.10 (+0.47%)
     
  • Crude Oil

    65.44
    -0.64 (-0.97%)
     
  • Gold

    1,817.00
    -5.80 (-0.32%)
     
  • Silver

    27.12
    -0.12 (-0.46%)
     
  • EUR/USD

    1.2079
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.6950
    +0.0710 (+4.37%)
     
  • Vix

    27.59
    +5.75 (+26.33%)
     
  • GBP/USD

    1.4062
    +0.0005 (+0.03%)
     
  • USD/JPY

    109.7300
    +0.0700 (+0.06%)
     
  • BTC-USD

    50,944.04
    -6,868.78 (-11.88%)
     
  • CMC Crypto 200

    1,389.45
    -174.38 (-11.15%)
     
  • FTSE 100

    7,004.63
    +56.64 (+0.82%)
     
  • Nikkei 225

    27,666.64
    -480.87 (-1.71%)
     

BioNTech SE Sponsored ADR (BNTX) Moves 6.7% Higher: Will This Strength Last?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

BioNTech SE Sponsored ADR (BNTX) shares rallied 6.7% in the last trading session to close at $122.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 15.6% gain over the past four weeks.

BNTX extended its rally driven by optimism over the company’s request to different regulatory agencies to expand emergency use of its COVID-19 vaccine for use in adolescents aged 12 to 15 years.

Price and Consensus

Price Consensus Chart for BNTX
Price Consensus Chart for BNTX

This company is expected to post quarterly earnings of $2.66 per share in its upcoming report, which represents a year-over-year change of +1123.1%. Revenues are expected to be $1.66 billion, up 5349.1% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For BioNTech SE Sponsored ADR, the consensus EPS estimate for the quarter has been revised 83.2% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on BNTX going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research